| Identification | Back Directory | [Name]
BENAZEPRILAT | [CAS]
86541-78-8 | [Synonyms]
Cibacen
CGS-14831
BENAZEPRILAT
BENAZEPRILAT HCL HYDRATE
Benazepril Related CoMpound C
BENAZEPRILAT HYDROCHLORIDE HYDRATE
(3S)-3-[[(S)-1-Carboxy-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid
(3S)-3-[[(1S)-1-carboxy-3-phenylpropyl]aMino-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine]-1-acetic acid
1H-1-Benzazepine-1-acetic acid, 3-(1S)-1-carboxy-3-phenylpropylamino-2,3,4,5-tetrahydro-2-oxo-, (3S)-
Benazepril Related Compound C (50 mg) ((3S)-3-[[(1S)-1-
carboxy-3-phenylpropyl]amino-2,3,4,5-tetrahydro-2-oxo-
1H-1-benzazepine]-1-acetic acid) | [Molecular Formula]
C22H24N2O5 | [MDL Number]
MFCD00864465 | [MOL File]
86541-78-8.mol | [Molecular Weight]
396.44 |
| Chemical Properties | Back Directory | [Appearance]
Crystalline Solid | [Melting point ]
270-272°C | [alpha ]
D -200.5° (c = 1 in 3% aqueous NH4OH) | [Boiling point ]
711.3±60.0 °C(Predicted) | [density ]
1.34±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer, Under Inert Atmosphere | [solubility ]
Aqueous Base (Slightly), DMSO (Slightly) | [form ]
Solid | [pka]
2.17±0.10(Predicted) | [color ]
White to Off-White | [CAS DataBase Reference]
86541-78-8 |
| Hazard Information | Back Directory | [Chemical Properties]
Crystalline Solid | [Uses]
A metabolite of Benazepril, which is used as an antihypertensive | [Definition]
ChEBI: A benzazepine that is 1,3,4,5-tetrahydro-2H-1-benzazepin-2-one in which the hydrogen attached to the nitrogen is replaced by a carboxy methyl group and in which the 3-pro-S hydrogen is replaced by the amino
roup of (2S)-2-amino-4-phenylbutanoic acid. An angiotensin-converting enzyme inhibitor, it is used as its monoester prodrug benazepril in the treatment of hypertension and heart failure. | [in vivo]
Benazeprilat (10 mg/kg, intravenous injection) and amlodipine (0.5 mg/kg, intravenous injection) in combination produce great hypotensive effect[2].
Benazepril (0.7 mg/kg, oral) markedly influences the dynamics of systemic RAAS peptides, resulting in a substantial decrease in AII and ALD while increasing PRA and AI[3]. | Animal Model: | Male SHR (14-16 weeks of age, 250-350 g)[2]. | | Dosage: | 10 mg/kg | | Administration: | I.V; once a day for 2 days. | | Result: | Produced hypotensive effect. |
| Animal Model: | Beagle dogs (12.0-19.5 kg)[3]. | | Dosage: | 0.7 mg/kg | | Administration: | P.O, once a day for 5 days. | | Result: | Effected systemic RAAS peptides. |
| [storage]
Store at -20°C |
|
| Company Name: |
OPULENT PHARMA
|
| Tel: |
+91-9106692785 +91-9106692785 |
| Website: |
www.www.NOWEBSITE |
|